Last reviewed · How we verify
JNJ-77242113
JNJ-77242113 is a selective inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular signaling in the brain to modulate neuronal activity.
JNJ-77242113 is a selective inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular signaling in the brain to modulate neuronal activity. Used for Schizophrenia, Bipolar disorder (exploratory).
At a glance
| Generic name | JNJ-77242113 |
|---|---|
| Also known as | PN-21235, PN-235, PN-21235, |
| Sponsor | Janssen Research & Development, LLC |
| Drug class | Phosphodiesterase 10A (PDE10A) inhibitor |
| Target | PDE10A |
| Modality | Small molecule |
| Therapeutic area | Neurology/Psychiatry |
| Phase | Phase 3 |
Mechanism of action
PDE10A is predominantly expressed in medium spiny neurons of the striatum. By inhibiting PDE10A, the drug increases cyclic nucleotide levels (cAMP and cGMP), enhancing downstream signaling pathways involved in motor control and cognitive function. This mechanism is being explored for neuropsychiatric and movement disorders where striatal dysfunction plays a role.
Approved indications
- Schizophrenia
- Bipolar disorder (exploratory)
Common side effects
- Nausea
- Headache
- Dizziness
- Akathisia
Key clinical trials
- A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis (PHASE3)
- A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis (PHASE3)
- A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet) (PHASE3)
- A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis (PHASE3)
- A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease (PHASE2, PHASE3)
- A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis (PHASE3)
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JNJ-77242113 CI brief — competitive landscape report
- JNJ-77242113 updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI